Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Price Target at $41.44

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has been given a consensus recommendation of “Moderate Buy” by the ten brokerages that are covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $41.44.

Several analysts recently weighed in on the company. B. Riley restated a “buy” rating and issued a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Chardan Capital reiterated a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR stock opened at $12.69 on Thursday. The company’s 50-day simple moving average is $17.70 and its two-hundred day simple moving average is $19.43. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. Arrowhead Pharmaceuticals has a one year low of $11.89 and a one year high of $30.41. The company has a market capitalization of $1.74 billion, a P/E ratio of -2.45 and a beta of 0.92.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.97). As a group, equities analysts anticipate that Arrowhead Pharmaceuticals will post -2.42 EPS for the current year.

Insider Activity

In other news, CFO Kenneth Allen Myszkowski sold 27,167 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $19.83, for a total transaction of $538,721.61. Following the transaction, the chief financial officer now owns 473,433 shares in the company, valued at $9,388,176.39. This represents a 5.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider James C. Hamilton sold 32,729 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $648,688.78. Following the completion of the sale, the insider now owns 272,122 shares of the company’s stock, valued at $5,393,458.04. This trade represents a 10.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 274,797 shares of company stock worth $4,830,279. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. R Squared Ltd acquired a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at about $38,000. GF Fund Management CO. LTD. acquired a new position in Arrowhead Pharmaceuticals in the 4th quarter worth approximately $49,000. Van ECK Associates Corp raised its position in Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock worth $56,000 after buying an additional 1,250 shares during the last quarter. KBC Group NV raised its position in Arrowhead Pharmaceuticals by 45.9% during the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock worth $98,000 after buying an additional 1,644 shares during the last quarter. Finally, Mackenzie Financial Corp acquired a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at approximately $137,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.